- Home
- DMA vs FBIO Comparison
DMA vs FBIO Comparison
Compare DMA & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | FBIO |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 78.3M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | DMA | FBIO |
|---|---|---|
| Price | $7.43 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 27.7K | ★ 251.3K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.22 |
| Revenue Next Year | N/A | $40.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.27 | $1.66 |
| 52 Week High | $9.15 | $4.53 |
Technical Indicators
Market Signals| Indicator | DMA | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 30.27 | 41.10 |
| Support Level | $7.27 | $2.20 |
| Resistance Level | $8.89 | $2.49 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 10.58 | 24.32 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.